All Blogs
Jul 07, 2026
Novartis to Acquire Myricx Bio; Roche’s Divarasib Tops Approved KRAS G12C Inhibitors in Phase III NSCLC Trial; Otsuka Reports Positive Two-Year Phase 3 Results for VOYXACT in IgA Nephropathy; Revolution Medicines Reports Early Clinical Data for Zoldonrasib Combination Regimens at ESMO GI 2026; Can-Fite Completes Patient Enrolment for Interim Analysis in Pivotal Phase 3 Psoriasis Trial
Novartis to Acquire Myricx Bio to Expand Next-Generation ADC Portfolio Novartis has signed an agreement to acquire Myricx Bio, a privately owned biotechnology company based in the UK that is developing a novel class of antibody-drug conjugates (ADCs) featuring N-myristoyltransferase inhibitor (NMTi) payloads. ...
Read More...
Jul 06, 2026
Paragangliomas and Pheochromocytomas Treatment Space Steps into the Precision Therapy Era
Summary Pheochromocytoma and paraganglioma (PCPG/PPGL) are rare neuroendocrine tumors that arise from chromaffin cells and can occur in the adrenal glands or in extra-adrenal sites such as the thorax, abdomen, pelvis, bladder, and head and neck. Surgery remains the only curative option for localized disease,...
Read More...
Jul 03, 2026
The Future of Degenerative Disc Disease Treatment: Moving Beyond Symptom Relief with Cell Therapy
Summary In the US, chronic low back pain affects about 28% of the population, and DDD is estimated to account for roughly half of specific CLBP cases, or around 14 million diagnosed prevalent cases in 2025. Standard care includes pain relief, NSAIDs, physical therapy, lifestyle changes, injections, and surge...
Read More...
Jul 02, 2026
STARMED Secures FDA 510(k) Clearance for Benign Thyroid Nodule Ablation; SciBase Advances U.S. Expansion with FDA 510(k) Submission for Nevisense; ALR Technologies to Acquire CGM Medical Technology in US$45 Million and 200 Million Share Deal; Co-Diagnostics Completes Validation Studies Ahead of FDA 510(k) Submission for Upper Respiratory Point-of-Care Test; Corvention Launches Innovative Balloon Catheter in the U.S. Following First Clinical Case; OrthAlign Reports First Clinical Cases Using Lantern® ASC System
STARMED Received FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication On 01 July 2026, STARMED America announced that it had received FDA 510(k) clearance for the first radiofrequency ablation (RFA) system in the United States specifically indicated for the treatment of benign thyroid nodules. Th...
Read More...
Jul 01, 2026
DNA Diagnostics: Transforming Precision Medicine and Redefining Disease Detection
DNA diagnostics is no longer a niche laboratory technique reserved for research institutions, it has become one of the fastest-growing pillars of modern medicine. By analyzing genetic material to detect mutations, pathogens, and chromosomal abnormalities, DNA-based testing is transforming how diseases are predicted...
Read More...
Jun 30, 2026
Zymeworks Announces Acquisition of Theravance Biopharma; Ipsen to Acquire Kartos Therapeutics; Viridian Therapeutics Wins U.S. FDA Approval for Lumvoa; Replimune Reaches FDA Milestone with RP1 BLA Resubmission Acceptance; Epicrispr Announces Encouraging Clinical Data for EPI-321 in FSHD
Zymeworks Signs Definitive Agreement to Acquire Theravance Biopharma Zymeworks Inc. has signed a definitive agreement to acquire Theravance Biopharma, Inc., marking a strategic step in expanding its commercial portfolio. The acquisition will bring YUPELRI®, the first and only once-daily nebulized long-acting mus...
Read More...
Jun 29, 2026
Ionis’ TRYNGOLZA Approval Raises the Stakes in the Triglyceride-Lowering Race
Summary Over 3 million Americans live with sHTG, including around 1 million high-risk patients with triglycerides ≥880 mg/dL or ≥500 mg/dL plus a history of acute pancreatitis or other comorbidities. In June 2026, the FDA approved Ionis’ TRYNGOLZA (already approved for FCS in 2024) as the first and only trea...
Read More...
Jun 26, 2026
TRODELVY’s First-Line TNBC Approval: Gilead’s Big Bet Reshapes the TROP2 ADC Battlefield
Summary TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression. TRODELVY sets a new standard as Europe’s first ADC and first novel therapy in two decades for eligible patients with first-line metastatic triple-negative breast cancer. Approval was based on AS...
Read More...
Jun 25, 2026
Legacy Expands Diagnostic Portfolio with New York CLEP Approval for Two LDTs; Quest Diagnostics Expands Patient Access to ctDNA MRD Testing with New York Approval of Haystack MRD; MVZ MedDiagnost and Sectra Ink 10-Year Deal to Unify Radiology Network Across 10 Sites; ALZpath and Abbott Enter Global Licensing Deal to Expand Blood-Based Alzheimer’s Diagnostics; Corvention Reaches Key Commercial Milestone with First U.S. Procedure and Balloon Catheter Launch; ZETA SURGICAL® Achieves First Clinical Milestone with Initial Patient Treatment at HOPE Therapeutics
Legacy Received New York State CLEP Approval for Two Laboratory-Developed Tests: Semen Analysis and DNA Fragmentation On 24 June 2026, Legacy announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, had validated and approved it...
Read More...
Jun 24, 2026
Fusion Biopsy: The Next Generation of Prostate Cancer Detection
Prostate cancer remains the second most common malignancy diagnosed in men worldwide, with global incidence now exceeding 1.4 million new prostate cancer cases a year. For decades, the diagnostic pathway leaned on a blunt instrument: a 12-core systematic biopsy taken largely by anatomical guesswork. That era is clo...
Read More...